Stocklytics Platform
Asset logo for symbol MNKD
MannKind
MNKD85
$5.85arrow_drop_up0.86%$0.05
High Quality
High Growth
Asset logo for symbol MNKD
MNKD85

$5.85

arrow_drop_up0.86%

Performance History

Chart placeholder
Key Stats
Open$5.89
Prev. Close$5.80
EPS0.04
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range5.69
5.89
52 Week Range3.17
6.04
Ratios
EPS0.04

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Asset logo for symbol LLY
Eli Lilly & Co
LLY74
Price$804.62
Perf. (24h)
arrow_drop_down2.01%-$16.57
Market Cap$738.87B
Asset logo for symbol UNH
UnitedHealth Group
UNH71
Price$569.71
Perf. (24h)
arrow_drop_up1.79%$10.03
Market Cap$527.83B
Asset logo for symbol JNJ
Johnson & Johnson
JNJ62
Price$160.64
Perf. (24h)
arrow_drop_up0.62%$1.00
Market Cap$382.01B
Asset logo for symbol ABBV
AbbVie
ABBV62
Price$185.16
Perf. (24h)
arrow_drop_up1.64%$2.99
Market Cap$326.96B

About MannKind (MNKD)

MannKind Corp (MNKD) is a biopharmaceutical company specializing in the development and commercialization of inhaled therapeutic products. The company was founded in 1991 and is headquartered in Westlake Village, California. MannKind Corp's flagship product is Afrezza, an inhaled insulin treatment for patients with diabetes. Afrezza is a rapid-acting, dry powder insulin that is delivered using the company's proprietary inhalation device. The product offers an alternative to traditional injectable insulin and provides patients with a more convenient and discreet method of administration.
MannKind Corp has experienced significant fluctuations in its stock price history. The company went public in 2004 at a price of $15 per share. However, the stock price declined over the years and reached a low of $0.67 per share in 2017. Since then, the stock price has shown some signs of recovery, reaching a high of $3.45 per share in 2020. As of the latest trading session, the stock price is $2.18 per share.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Michael E. Castagna Pharm.D.
Headquarters
Danbury
Employees
391
Exchange
NASDAQ
add MannKind to watchlist

Keep an eye on MannKind

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is MannKind's (MNKD) price per share?
The current price per share for MannKind (MNKD) is $5.85. The stock has seen a price change of $0.05 recently, indicating a 0.86% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for MannKind (MNKD)?
For MannKind (MNKD), the 52-week high is $6.04, which is 3.25% from the current price. The 52-week low is $3.17, the current price is 84.54% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is MannKind (MNKD) a growth stock?
MannKind (MNKD) has shown an average price growth of 0.41% over the past three years. It has received a score of 50 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying MannKind as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is MannKind (MNKD) stock price performance year to date (YTD)?
As of the latest data, MannKind (MNKD) has a year-to-date price change of 49.23%. Over the past month, the stock has experienced a price change of 11.64%. Over the last three months, the change has been 39.95%. Over the past six months, the figure is 70.06%. Looking at a longer horizon, the five-year price change stands at 446.73%.
help
Is MannKind (MNKD) a profitable company?
MannKind (MNKD) has a net income of -$11.94M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 68.45% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 23.13% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $198.96M, with a revenue growth rate of 99.42%, providing insight into the company's sales performance and growth. The gross profit is $136.19M. Operating income is noted at $10.59M. Furthermore, the EBITDA is $45.39M.
help
What is the market capitalization of MannKind (MNKD)?
MannKind (MNKD) has a market capitalization of $1.56B. The average daily trading volume is 2.59M, indicating the stock's liquidity and investor engagement.

News

"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker
INVESTING
6/27/2024

"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker

INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
HEALTH
PRODUCT / SERVICES ANNOUNCEMENT
CLINICAL STUDY
6/22/2024

INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions

Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
CALENDAR OF EVENTS
CLINICAL STUDY
6/5/2024

Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions

MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix
PARTNERSHIPS
PRODUCT / SERVICES ANNOUNCEMENT
5/29/2024

MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix

MannKind Outperforms As Tyvaso DPI Captures Market Share
5/15/2024

MannKind Outperforms As Tyvaso DPI Captures Market Share

MannKind (MNKD) Upgraded to Strong Buy: Here's Why
5/13/2024

MannKind (MNKD) Upgraded to Strong Buy: Here's Why

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level